Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Kairos Pharma is a clinical-stage biopharmaceutical company developing innovative cancer therapies targeting immune suppression and drug resistance. Its portfolio includes antibodies and small molecules for prostate, lung, breast cancers, and glioblastoma. Leveraging proprietary technologies licensed from Cedars-Sinai, the company focuses on immunotherapies that modulate tumor microenvironments, address resistance mechanisms, and enhance immune response, aiming to transform cancer treatment through novel, targeted drug development.
This description was generated via AI from an annual report. Updated about 1 year ago.